💊
Tuzulby
methylphenidate hydrochloride
Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung
✅ Autorisiert
✅
Keine aktiven Warnungen
Dieses Arzneimittel unterliegt derzeit keinen Lieferengpässen, Sicherheitshinweisen oder Rückrufen.
Wofür es verwendet wird
Tuzulby is indicated as part of a comprehensive treatment programme for attention-deficit / hyperactivity disorder (ADHD) in children and adolescents 6-17 years old when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders. Diagnosis should be made according to Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria or the guidelines in International Classification of Diseases, Tenth Revision (ICD-10) and should be based on a complete history and evaluation of the patient. Diagnosis cannot be made solely on the presence of one or more symptoms.
⚠️ Patientensicherheit
No
Offizielle EMA-Seite
https://www.ema.europa.eu/en/medicines/human/EPAR/tuzulby